Alzheimer’s Disease Diagnostic Market to Reach USD $11.82 Billion by 2030 at 10.3% CAGR
Alzheimer’s Disease Diagnostic Market Report 2026_Segment
Alzheimer’s Disease Diagnostic Market Drivers & Restraints 2026_Driver
Alzheimer’s Disease Diagnostic Market Regional Share 2026_Region
The Business Research Company's Alzheimer’s Disease Diagnostic Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035
LONDON, GREATER LONDON, UNITED KINGDOM, April 30, 2026 /EINPresswire.com/ -- "Alzheimer’s Disease Diagnostic market to surpass $12 billion in 2030. In comparison, the Physicians And Other Health Practitioners market, which is considered as its parent market, is expected to be approximately $2,449 billion by 2030, with Alzheimer’s Disease Diagnostic to represent around 0.5% of the parent market. Within the broader Healthcare Services industry, which is expected to be $11,318 billion by 2030, the Alzheimer’s Disease Diagnostic market is estimated to account for nearly 0.1% of the total market value.
Which Will Be The Biggest Region In The Alzheimer’s Disease Diagnostic Market In 2030?
North America will be the largest region in the Alzheimer’s disease diagnostic market in 2030, valued at $4.6 billion. The market is expected to grow from $2.9 billion in 2025 at a compound annual growth rate (CAGR) of 10%. The strong growth can be attributed to the high prevalence of Alzheimer’s disease and aging population, widespread availability of advanced diagnostic infrastructure, increasing adoption of biomarker-based testing and neuroimaging technologies, strong presence of leading diagnostic companies and research institutions, growing awareness regarding early diagnosis, and significant investments in precision medicine and neurodegenerative disease research across the USA and Canada.
Which Will Be The Largest Country In The Global Alzheimer’s Disease Diagnostic Market In 2030?
The USA will be the largest country in the Alzheimer’s disease diagnostic market in 2030, valued at $4.3 billion. The market is expected to grow from $2.7 billion in 2025 at a compound annual growth rate (CAGR) of 10%. The strong growth can be attributed to the rising burden of cognitive disorders, high healthcare expenditure, rapid adoption of advanced diagnostic techniques such as PET imaging and blood-based biomarkers, increasing clinical trials and drug development activities for Alzheimer’s disease, strong reimbursement frameworks, and the presence of major diagnostic laboratories and technology providers driving early detection and disease management.
Request A Free Sample Of The Alzheimer’s Disease Diagnostic Market Report
https://www.thebusinessresearchcompany.com/sample_request?id=21093&type=smp&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Apr_PR
What Will Be The Largest Segment In The Alzheimer’s Disease Diagnostic Market In 2030?
The alzheimer’s disease diagnostic market is segmented by type into triage, diagnosis, and screening. The diagnosis segment will be the largest segment of the Alzheimer’s disease diagnostic market segmented by type, accounting for 49% or $6 billion of the total in 2030. The diagnosis segment will be supported by the increasing demand for accurate and confirmatory diagnostic tools, rising use of advanced imaging modalities such as MRI and PET scans, growing adoption of cerebrospinal fluid (CSF) and blood-based biomarker tests, expanding clinical guidelines emphasizing early and precise diagnosis, and continuous technological advancements aimed at improving diagnostic sensitivity, specificity, and clinical decision-making in Alzheimer’s disease management.
The alzheimer’s disease diagnostic market is segmented by diagnostic technique into biomarkers, imaging techniques, genetic testing, and cognitive assessment tests.
The alzheimer’s disease diagnostic market is segmented by end user into clinics, hospitals, diagnostic centers, pharmaceutical companies, and academic research centers.
What Is The Expected CAGR For The Alzheimer’s Disease Diagnostic Market Leading Up To 2030?
The expected CAGR for the alzheimer’s disease diagnostic market leading up to 2030 is 10%.
What Will Be The Growth Driving Factors In The Global Alzheimer’s Disease Diagnostic Market In The Forecast Period?
The rapid growth of the global Alzheimer’s disease diagnostic market leading up to 2030 will be driven by the following key factors that are expected to reshape early detection capabilities, biomarker innovation, diagnostic accuracy, AI and machine learning integration in diagnostic tools, and personalized treatment approaches across the global healthcare ecosystem.
Development Of Blood-Based Biomarkers For Non-Invasive Diagnosis – The development of blood-based biomarkers for non-invasive diagnosis is expected to become a major growth driver for the Alzheimer’s disease diagnostic market by 2030. Traditional diagnostic methods such as cerebrospinal fluid (CSF) analysis and neuroimaging are often invasive, expensive, and less accessible, creating a strong need for simpler alternatives. Blood-based biomarker tests offer a minimally invasive, cost-effective, and scalable solution for early detection and monitoring of Alzheimer’s disease. These tests enable broader population screening, improve patient compliance, and support earlier clinical intervention. Diagnostic companies are increasingly investing in high-sensitivity assays targeting biomarkers such as amyloid-beta and tau proteins. As a result, the development of blood-based biomarkers is anticipated to contribute approximately 3.0% annual growth to the market.
Rising Demand For Personalized Medicine And Precision Diagnostics – The rising demand for personalized medicine and precision diagnostics is expected to significantly drive the Alzheimer’s disease diagnostic market by 2030. Advances in genomics, proteomics, and biomarker profiling are enabling more tailored diagnostic approaches that align with individual patient characteristics and disease progression patterns. Personalized diagnostics support targeted therapeutic strategies, improve clinical outcomes, and enhance the effectiveness of emerging disease-modifying treatments. Healthcare providers are increasingly adopting precision diagnostic tools to stratify patients, monitor disease progression, and optimize treatment plans. This shift toward individualized care is reinforcing the importance of advanced diagnostic solutions. Consequently, the rising demand for personalized medicine and precision diagnostics is projected to contribute around 2.8% annual growth to the market.
Integration Of AI And Machine Learning In Diagnostic Tools For Early Detection – The integration of AI and machine learning in diagnostic tools for early detection is expected to emerge as a key factor accelerating the growth of the Alzheimer’s disease diagnostic market by 2030. AI-driven algorithms are enhancing the accuracy and speed of diagnostic processes by analyzing complex datasets from imaging, biomarkers, and clinical records. These technologies enable early identification of subtle disease patterns that may not be detectable through conventional methods. AI-powered diagnostic platforms also improve workflow efficiency, reduce diagnostic variability, and support clinical decision-making. As healthcare systems increasingly adopt digital health solutions, the role of AI in Alzheimer’s diagnostics is expanding rapidly. Therefore, the integration of AI and machine learning in diagnostic tools is projected to contribute approximately 2.5% annual growth to the market.
Access The Detailed Alzheimer’s Disease Diagnostic Market Report Here
https://www.thebusinessresearchcompany.com/report/alzheimers-disease-diagnostic-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Apr_PR
What Are The Key Growth Opportunities In The Alzheimer’s Disease Diagnostic Market In 2030?
The most significant growth opportunities are anticipated in the triage market, the diagnosis market, and the screening market within the Alzheimer’s disease diagnostic market. Collectively, these segments are projected to contribute over $4 billion in market value by 2030, driven by the increasing emphasis on early disease detection, rising adoption of biomarker-based diagnostic techniques, growing availability of non-invasive testing solutions, and expanding integration of advanced imaging and AI-driven diagnostic tools. This momentum reflects the healthcare industry’s focus on improving clinical outcomes through early intervention, enhancing diagnostic accuracy, and supporting the development of targeted therapies, thereby accelerating growth across the global Alzheimer’s diagnostic ecosystem.
The triage market is projected to grow by $1 billion, the diagnosis market by $2 billion, and the screening market by $1 billion over the next five years from 2025 to 2030.
Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. We have published over 17,500 reports across 27 industries and 60+ geographies. Our research is powered by 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.
We provide continuous and custom research services, offering a range of specialized packages tailored to your needs, including Market Entry Research Package, Competitor Tracking Package, Supplier & Distributor Package and much more.
Disclaimer: Please note that the findings, conclusions and recommendations that TBRC Business Research Pvt Ltd delivers are based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such TBRC Business Research Pvt Ltd can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect. Analysis and findings included in TBRC reports and presentations are our estimates, opinions and are not intended as statements of fact or investment guidance."
Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
